Abstract
The coronavirus disease 2019 pandemic has had an unprecedented effect on health and health care and posed challenges to the conduct of clinical trials.Targeted mitigating strategies, on the basis of early and continued data collection from site surveys, limited disruption to the ASCEND trials.Flexibly allowing hemoglobin assessment at local laboratories to inform randomized treatment dosing was key to limiting the discontinuation of treatment.
Keywords: COVID-19; SARS-CoV-2; chronic kidney disease; clinical trial; dialysis; pandemics.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, clinical trial, Chronic kidney disease, dialysis, Pandemics, 【초록키워드】 Treatment, coronavirus disease, Coronavirus disease 2019, clinical trial, pandemic, Health care, clinical trials, Chronic kidney disease, dialysis, kidney, Randomized, Health, Pandemics, Kidney disease, hemoglobin, Care, Data collection, local laboratories, discontinuation of treatment, local laboratory, 【제목키워드】 clinical, challenge, Program, experience, Conducting, the SARS-CoV-2,
【저자키워드】 COVID-19, SARS-CoV-2, clinical trial, Chronic kidney disease, dialysis, Pandemics, 【초록키워드】 Treatment, coronavirus disease, Coronavirus disease 2019, clinical trial, pandemic, Health care, clinical trials, Chronic kidney disease, dialysis, kidney, Randomized, Health, Pandemics, Kidney disease, hemoglobin, Care, Data collection, local laboratories, discontinuation of treatment, local laboratory, 【제목키워드】 clinical, challenge, Program, experience, Conducting, the SARS-CoV-2,
{{{ 추상적인 }}}
2019년 코로나바이러스 전염병은 건강 및 건강 관리에 전례 없는 영향을 미쳤으며 임상 시험 수행에 어려움을 주었습니다. 현장 조사에서 초기 및 지속적인 데이터 수집을 기반으로 하는 표적 완화 전략은 ASCEND 시험 중단을 제한했습니다.유연하게 지역 실험실에서 헤모글로빈 평가를 허용하여 무작위 치료 투여량을 알려주는 것이 치료 중단을 제한하는 핵심이었습니다.
{{ 키워드: }} 코로나19; 사스 코로나바이러스 2; 만성 신장 질환; 임상 시험; 투석; 전염병.